Results

Total Results: 2,505 records

Showing results for "diseases".

321. Nonsurgical Treatments for Urinary Incontinence in Adult Women: (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/urinary-incontinence-update_research-protocol.pdf
     June 06, 2017 - neurogenic bladder (due to, for example, spinal cord injury, stroke, multiple sclerosis, or Parkinson disease … Which patient characteristics, including age, type of UI, severity of UI, baseline diseases that affect … Which patient characteristics, including age, type of UI, severity of UI, baseline diseases that affect … Which patient characteristics, including age, type of UI, severity of UI, baseline diseases that affect … , pregnant women, institutionalized or hospitalized participants, have UI caused by neurological disease

322. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_research-protocol.pdf
     March 09, 2010 - arthritis (JIA), formerly known as juvenile rheumatoid arthritis, is the most common rheumatologic disease … with more destructive joint disease … Evaluating changes in JIA disease status can be challenging. … First, these measures evaluate relative and not absolute changes in disease progression. … Effects of Omega-3 Fatty Acids on Cardiovascular Disease.

323. What do we know about how evidence of harm and benefit is communicated in other countries? (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/communicating_risk_international_king.ppt
     January 01, 2005 - Approaches in the Medical Literature Many examples of descriptive reports of tools used for single diseases … Understanding NICE guidance—information for people who have or are at increased risk of cardiovascular disease

324. Data Points 13: Use of Preoperative Breast MRI among older women with ductal carcinoma in situ and locally invasive breast cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/dcis-mri-utilization_research.pdf
     August 01, 2012 - increased dramatically from 2002 to 2007 for both women with DCIS (<1% to 12.9%) and with invasive disease … Specifically, we included International Classification of Diseases for Oncology, Third Edition (ICD-O … Among women with invasive cancer, rates of MRI use de- creased with higher grade disease. … The increase was observed for both women with DCIS and early invasive disease. … ) received more MRIs prior to surgery than those with lower risk disease.

325. Multiple-Sclerosis Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/multiple-sclerosis_executive.pdf
     April 01, 2015 - Analytic framework for discontinuing disease-modifying treatments for MS DMT = disease-modifying treatment … and disease activity after interrupting treatment. … stages of the disease, when the side effects are less than disease symptoms. … course to prevent or delay disease progression. … We cannot currently predict early or benign disease courses.

326. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/psoriasis-chronic_research-protocol.pdf
     January 10, 2012 - duration, baseline disease severity, affected BSA, disease location, number and type of previous treatments … oral solution, intra- lesional) ‡ Approved for use in endocrine and rheumatic disorders; collagen diseases … ; dermatologic diseases including pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme … mycosis fungoides, severe psoriasis, and severe seborrheic dermatitis; allergic states; ophthalmic diseases … ; respiratory disease; hematologic disorders; neoplastic disease; edematous states; gastrointestinal

327. Restless-Legs Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/restless-legs_research-protocol.pdf
     December 16, 2011 - and Objectives for the Systematic Review Overview Restless legs syndrome (RLS) or Willis-Ekbom disease … If the disease progresses, symptoms may occur earlier in the day and intensify even further at night … are used to assess disease severity and treatment- induced changes in disease status. … Yet, the disease is chronic, often requiring life-long treatment. … and definition of clinically significant change in disease status used in individual studies.

328. Outcomes in COPD patients treated with theophylline (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/decide16final-mortality-risk-in-copd-pts-using-theophylline.pdf
     December 01, 2009 - Mortality risk in chronic obstructive pulmonary disease patients using theophylline. … disease (PUD), gastroesophogeal reflux disease (GERD), arrhythmias, depression, hypertension, ischemic … A 4-year trial of tiotropium in chronic obstructive pulmonary disease. … The use of theophylline in chronic obstructive pulmonary disease. … Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease.

329. Outcomes in COPD patients treated with theophylline (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/copd-management_research.pdf
     December 01, 2009 - Mortality risk in chronic obstructive pulmonary disease patients using theophylline. … disease (PUD), gastroesophogeal reflux disease (GERD), arrhythmias, depression, hypertension, ischemic … A 4-year trial of tiotropium in chronic obstructive pulmonary disease. … The use of theophylline in chronic obstructive pulmonary disease. … Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease.

330. Data-Points 1 Diabetic-Foot-Ulcers Data 02-2011 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/data-points_1_diabetic-foot-ulcers_data_02-2011.pdf
     January 01, 2011 - Diabetes Rate in Enrolled Population Total All 2006 32.8 8.7 26.4% Age Disabled/end stage renal disease … Alaska Native 2006 0.1 0.1 36.0% Total All 2007 32.3 8.8 27.3% Age Disabled/end stage renal disease … Alaska Native 2007 0.2 0.1 37.3% Total All 2008 31.9 8.9 27.9% Age Disabled/end stage renal disease … Alaska Native 2006 9.7% 28.4% 6.4% Total All 2007 8.1% 18.9% 5.0% Age Disabled/end stage renal disease … Without Diabetes and Without PAD Total All 2006 3.3% 11.0% 2.5% Age Disabled/end stage renal disease

331. Arthritis-Psoriatric Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_executive.pdf
     April 01, 2012 - The condition is associated with the skin disease psoriasis, but not all people with psoriasis will … Additionally, PsA may predate the development of skin disease, leading to some diagnostic uncertainty … Available therapies for PsA include corticosteroids, oral disease-modifying antirheumatic drugs or … Analytic framework for treatment for psoriatic arthritis DMARDS = disease-modifying antirheumatic … * American College of Rheumatology measure of disease activity: response scores based on 20, 50, or

332. PATIENTSLIKEME (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/clifford.pdf
     May 29, 2025 - And we started out as an ALS -- I've been in the U.K. a lot so I say motor neuron disease, so pardon … going to be, you know, at the early part of the journey, getting married after some onset of the disease … who's down at the end can teach the patient who's just diagnosed a tremendous amount about the disease … But some of our best patient populations are in diseases with complex presentation and complex etiology … So these are diseases where patients really don't know what to expect.

333. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-update_research-protocol.pdf
     May 07, 2010 - extensively for treatment of hypertension, heart failure, myocardial infarction, diabetes, and renal disease … disease or events, symptomatic coronary artery disease, end-stage renal disease, quality of life, … , and cerebrovascular disease- specific) o Morbidity (cardiac events [MI], heart failure, cerebral … vascular disease or events [including stroke], symptomatic coronary artery disease, end-stage renal … disease, peripheral vascular disease [as clinically manifest, not markers of], quality of life)

334. Version-3-Immunity-After-Covid-19-Appendix-Table-B-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19-appendix-table-B-1.xlsx
     January 24, 2022 - : 3 (8.6) Cardiovascular disease: 4 (11.4) CKD: 1 (2.9) Chronic lung disease: 3 (8.6) CMIA ELISA Abbott … ) Pulmonary disease: 2 (12.5) Heart disease: 2 (12.5) CLIA IgG, IgM ManglumiTM 2019 nCovIgM and the MaglumiTM … controlled cohort 10 HIV Adult COVID-19 patients who were hospitalized in the Department of Infectious Diseases … 2020 - 11/30/2020 COVID-19 patients >18 yrs old who were hospitalized in the Department of Infectious Diseases … patients) The Transplant Institute, Sahlgrenska University Hospital, and the Department of Infectious Diseases

335. Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/plasma-cell-dyscrasias-sflc-assay-future_research.pdf
     September 01, 2012 - monitoring.3,6 The SFLC assay may also be the only means of detecting a disease marker in some disease … o Studies of only patients with disease reflects the extreme end of the spectrum of disease severity … 1 *Polyclonal gammopathy is seen in a diverse range of inflammatory and neoplastic diseases where clonal … Poor, since PCD is a rare disease. … 1 *Polyclonal gammopathy is seen in a diverse range of inflammatory and neoplastic diseases where clonal

336. Draft - Primary Hypofractionated Radiation Therapy for Localized Prostate Cancer: Appendix D1 Tables (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypofractionated-radiation-therapy-draft-appendix-d1.xlsx
     January 01, 2024 - ≤60 ng/mL, WHO performance 0 to 2 Previous pelvis irradiation, radical prostatectomy, pelvic nodal disease … Gleason <= 6, and PSA <= 20 ng/mL; or T1 to 2, Gleason = 7, and PSA <= 20 ng/mL) without evidence of disease … Single Eligible patients included men with biopsy-confirmed prostate adenocarcinoma with high risk disease … All patients with high-risk disease were prescribed ADT for 2 years. … stenosis, colorectal surgery, repeated endoscopic examinations, interventions related to anorectal diseases

337. Considering the Range of Decision-Relevant Effects (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-choosing-outcomes.ppt
     June 01, 2012 - screening for reportable diseases such as syphilis or HIV. … An individual diagnosed with coronary disease might alter his or her lifestyle to reduce disease progression … Although the prognoses for some diseases are minimally modifiable with current treatments, most prognostic … asymptomatic individuals or individuals with unrecognized symptoms to detect as many different types of diseases … Screening tests should not be employed to detect as many diseases as possible, but rather only when there

338. Considering the Range of Decision-Relevant Effects (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-choosing-outcomes.ppt
     June 01, 2012 - screening for reportable diseases such as syphilis or HIV. … An individual diagnosed with coronary disease might alter his or her lifestyle to reduce disease progression … Although the prognoses for some diseases are minimally modifiable with current treatments, most prognostic … asymptomatic individuals or individuals with unrecognized symptoms to detect as many different types of diseases … Screening tests should not be employed to detect as many diseases as possible, but rather only when there

339. Disposition of Comments Report for Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/colorectal-cancer-liver-metastases-therapies_disposition-comments.pdf
     December 11, 2012 - For key questions 3 and 4 patients were excluded if extrahepatic disease was present. … It is estimated that only about 25% of patients truly present with metastatic disease. … who can only have their entire disease burden treated by some form of embolotherapy. … was not described as liver-dominant disease or minimally extra-hepatic disease. … for the vast majority individuals over the course of their disease.

340. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-2007_executive.pdf
     January 01, 2007 - extensively for treatment of hypertension, heart failure, myocardial infarction, diabetes, and renal disease … disease-specific mortality) and morbidity (cardiac events [myocardial infarction], heart failure, cerebral … vascular disease or events [including stroke], symptomatic coronary artery disease, end stage renal … disease, peripheral vascular disease, and quality of life). 4Safety outcomes considered were overall … (either based on creatinine, GFR, or renal disease) proteinuria).